TIXiMED
PrivateLast Round
Debt
Mar 13, 2026
Total Funding Raised
$4.85M
Momentum Score
25 /100
Company Overview
TIXiMED is a clinical-stage pharmaceutical company developing and commercializing a first-of-its-kind oral therapy for type 1 diabetes based on the inhibition of the protein TXNIP.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
TIXiMED Comps
Public and private peers based on sector, stage, and business model.
TIXiMED Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Mar 13, 2026 | ||||
| Debt | Dec 19, 2024 |
Key People
Founding team and executive leadership
TIXiMED Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Helmsley Charitable Trust | Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 13, 2026
$2.2M debt round completed.
TIXiMED Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about TIXiMED's valuation, stock price, and market status.
